Comparative Pharmacology
Head-to-head clinical analysis: FML S versus POLYTRIM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FML S versus POLYTRIM.
FML-S vs POLYTRIM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorometholone is a synthetic corticosteroid that binds to the glucocorticoid receptor, modulating gene expression to inhibit phospholipase A2 activity, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production. This results in decreased inflammation, edema, and immune cell infiltration. Sulfacetamide is a sulfonamide antibiotic that competitively inhibits dihydropteroate synthase, blocking folate synthesis and bacterial growth.
Polymyxin B sulfate binds to the lipopolysaccharide (LPS) in the outer membrane of Gram-negative bacteria, disrupting membrane integrity and causing cell death. Trimethoprim inhibits bacterial dihydrofolate reductase, blocking the conversion of dihydrofolic acid to tetrahydrofolic acid, thereby inhibiting bacterial DNA synthesis.
1-2 drops of 0.1% ophthalmic suspension into the conjunctival sac every 4 hours; may increase to every 2 hours in severe inflammation.
1 drop in the affected eye(s) every 4 hours for 7-10 days.
None Documented
None Documented
2.8-3.5 hours; prolonged to 8-12 hours in renal impairment or in neonates
Terminal elimination half-life of polymyxin B is 4.5-6 hours; for trimethoprim it is 8-10 hours. In renal impairment, half-life of both components is prolonged.
Renal (65-75% as unchanged drug and metabolites), biliary/fecal (15-25%)
Renal excretion accounts for approximately 40% of the dose as unchanged polymyxin B and 60% as unchanged trimethoprim. Biliary/fecal elimination is minimal (<5% for each component).
Category C
Category C
Ophthalmic Antibiotic/Corticosteroid Combination
Ophthalmic Antibiotic